+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment



The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment



Clinical Endocrinology 50(4): 517-527



OBJECTIVE Little is known about the natural history of polycystic ovary syndrome (PCOS), although preliminary data indicate that affected women are more susceptible than the general population to diabetes and cardiovascular diseases at post-menopausal ages. The aim of this study was to follow-up all main features of the metabolic syndrome in a group of young women with PCOS and to investigate the long-term effects on metabolism and body composition of oestrogen-progestagen (OP) compounds, which are frequently used in these women to treat hyperandrogenism and related clinical features. DESIGN Long-term follow-up study. SUBJECTS AND METHODS Thirty-seven women with PCOS were re-evaluated 10.3 +- 0.8 years (range 6-18 years) after their first assessments (age: before 19.8 +- 4.9 years; after 29.9 +- 4.4 years). When first examined, women were instructed to follow a hypocaloric diet if they were obese plus OP, if they agreed to such treatment. Main anthropometric parameters, basal sex hormones and lipids, fasting and glucose-stimulated glucose and insulin levels and several clinical data were recorded before and after follow-up. RESULTS In the whole group of women with PCOS we found no changes in body weight and fat mass, whereas both the waist-to-hip ratio and the waist-to-thigh ratio were significantly reduced. No significant changes occurred in mean fasting and glucose-stimulated glucose and insulin concentrations, whereas a significant increase in high-density lipoprotein-cholesterol was found. No significant changes occurred in testosterone levels. During the follow-up period 16 women took OP for an average of 97 +- 18 months (range 12-180 months) (OP-users) whereas 21 women never took OP (non-OP-users). All OP-users were still taking OP when re-evaluated at the follow-up examination. With respect to baseline values, body mass index was higher in non-OP-users than in their counterparts. Waist circumference (P<0.025), the waist-to-hip (P<0.05) and the waist-to-thigh (P<0.01) ratios decreased significantly only in the OP-users. In addition, percentage changes in waist circumference (P<0.05) and waist-to-hip ratio (P<0.05) during the follow-up period were significantly different between the groups. Glucose tolerance (as area under the curve (AUC)) improved (P<0.05) in OP-users but not in non-OP-users. Moreover, compared to baseline values, basal insulin levels were significantly (P<0.01) reduced in OP-users but not in non-OP-users. On the contrary, no significant change was found in insulinAUC in the former, whereas it significantly increased (P<0.05) in the latter. Accordingly, fasting C-peptide decreased (P<0.05) in OP-users, whereas both fasting (P<0.01) and stimulated (P<0.01) C-peptide significantly increased in non-OP-users. Changes in fasting or stimulated insulin and C-peptide in non-OP-users were not associated with parallel changes in testosterone levels. Total cholesterol and triglycerides did not change in either group, but HDL-cholesterol increased (P<0.05) only in OP-users. Sex hormone-binding globulin concentrations increased significantly (P<0.01) in OP-users, without any significant change in non-OP-users. Testosterone concentrations did not change significantly in either group, but the testosterone: SHBG ratio significantly decreased in OP-users (P<0.05) but not in the non-OP-users. Among the clinical features, acanthosis nigricans significantly (P<0.01) worsened in non-OP-users but not in the OP-users, without any significant change in the hirsutism and acne scores. Pregnancy rates during the follow-up were similar in both groups. CONCLUSIONS These data indicate that hyperinsulinaemia and insulin resistance tended to worsen spontaneously in women with PCOS, without any worsening of the hyperandrogenism. Long-term oestrogen-progestagen treatment countered this tendency, probably because it improved the pattern of body fat distribution, by reducing abdominal fat depots.

(PDF emailed within 0-6 h: $19.90)

Accession: 011527690

Download citation: RISBibTeXText

PMID: 10468913

DOI: 10.1046/j.1365-2265.1999.00701.x


Related references

Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertility and Sterility 96(5): 1271-1274, 2011

Women with polycystic ovary syndrome wedge resected in 1956 to 1965 a long term follow up focusing on natural history and circulating hormones. Fertility & Sterility 57(3): 505-513, 1992

Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecological Endocrinology 2018: 1-8, 2018

Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clinical Endocrinology 66(1): 103-109, 2007

Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome. Casopis Lekaru Ceskych 140(22): 688-694, 2002

Metabolic syndrome in young Czech women with polycystic ovary syndrome. Human Reproduction 20(12): 3328-3332, 2005

The metabolic syndrome in young Korean women with polycystic ovary syndrome. Diabetes Research and Clinical Practice 77 Suppl 1: S243-S246, 2007

Circulating Angptl8 Is Associated with the Presence of Metabolic Syndrome and Insulin Resistance in Polycystic Ovary Syndrome Young Women. Mediators of Inflammation 2019: 1-10, 2019

Optimal waist circumference for prediction of metabolic syndrome in young Korean women with polycystic ovary syndrome. Obesity: 3, 593-597, 2010

Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Human Reproduction 20(9): 2409-2413, 2005

Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Diabetes and Vascular Disease Research 6(2): 110-119, 2010

Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertility & Sterility 77(5): 936-944, 2002

Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clinical Endocrinology 75(4): 520-527, 2012

Long term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. 2011

Polycystic ovary syndrome: a common reproductive syndrome with long-term metabolic consequences. Hong Kong Medical Journal 23(6): 622-634, 2017